Preference Management Solution News Today

Federated learning allows AIs to train on patient data that never leaves local sites, but it’s not immune to AI bias and privacy challenges.

Genfit has signed an exclusivity agreement for the acquisition of clinical-stage biotechnology firm, Versantis, for $109m (Sfr105m).

The second edition of the Rare Disease Spotlight series investigates the trends in orphan drug designations across therapy areas over almost 40 years.

We analyse the impact of the war on the clinical trial landscapes of Ukraine and Russia, as investigators chronicle the situation on the ground.

AIM ImmunoTech leadership offers new details on a potential Phase II trial of Ampligen in long Covid patients with chronic fatigue.

To overcome the growing threat posed by antimicrobial resistance, a variety of approaches must be taken by pharma companies and governments.

From 2013 to 2015, there was a consistent increase in hepatitis C research efforts, with 2015 a record year for trial initiations.

Once Covid-19 lockdown restrictions began in March 2020, HIV testing volumes declined by as much as 50% compared with 2019 levels.

Alzheimer's disease is a progressive neurological disorder that causes brain atrophy and causes brain cells to die.

Health Canada accepted to review Arcutis Biotherapeutics’ NDS for roflumilast cream 0.3% to treat plaque psoriasis in adults and adolescents.